Fosamax and Osteonecrosis of the Jaw: Examining the Scientific Evidence

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Education to Targeted Safety Inquiry

The legacy of general health and science information has long provided the public with foundational knowledge about wellness, disease prevention, and the safe use of medical interventions. Within this broad domain, discussions of bone health and the management of osteoporosis have been prominent, often emphasizing the benefits of pharmacological treatments to maintain skeletal integrity. This heritage context naturally includes the introduction of bisphosphonate therapies, such as Fosamax, which were widely adopted for their efficacy in reducing fracture risk. As the public became more informed about these medications, attention gradually shifted from general therapeutic benefits to a more nuanced understanding of potential adverse effects. In the mass production setting, where large populations are exposed to standardized treatments, the need to monitor for rare but serious outcomes becomes critical. This pivot from general health education to occupational exposure concern arises when considering how widespread pharmaceutical use may lead to unintended consequences in specific patient subgroups. The transition focuses on the scientific evidence connecting Fosamax exposure to the risk of osteonecrosis of the jaw, moving from a broad health awareness framework to a targeted inquiry into causation. This shift underscores the importance of evaluating real-world outcomes in populations receiving mass-produced therapies, without delving into mechanistic details.

Understanding Fosamax and Its Mechanism

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism involves inhibiting bone resorption, which reduces fracture risk but also alters normal bone remodeling. A recognized adverse effect associated with bisphosphonate use, including Fosamax, is osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region. Clinical presentation typically involves areas of exposed bone that persist for weeks to months, often accompanied by pain, swelling, infection, or drainage. Diagnosis is based on clinical examination and imaging, with the hallmark being necrotic bone that fails to heal after dental procedures or spontaneously. The condition can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanistic Pathways Linking Fosamax to ONJ

The mechanistic pathways linking Fosamax to ONJ are rooted in bisphosphonate pharmacology. Bisphosphonates like alendronate accumulate in bone, particularly at sites of high turnover such as the jaw. They inhibit osteoclast activity, reducing bone resorption and remodeling. This suppression of normal bone turnover can impair the jawbone's ability to repair microdamage and respond to local stressors, such as dental infections or trauma. Multiscale characterization of jawbone in animal models treated with bisphosphonates has provided insights into these effects. In estrogen-deficient rats, treatment with alendronate altered jawbone properties, including static and dynamic mechanical stability of teeth in the alveolar socket, tissue mineral density distribution, and nanoindentation properties of the jawbone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077/). These changes suggest that bisphosphonate therapy can compromise the structural integrity and healing capacity of the jawbone, predisposing it to necrosis when additional insults occur.

Temporal Relationship and Risk Factors

The timeline between exposure to Fosamax and documented harm varies. The time to onset of ONJ symptoms can range from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, the risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). This temporal relationship underscores the importance of considering cumulative dose and treatment length when assessing risk. For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Adequacy of Warnings and Labeling

Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw under Warnings and Precautions. This section notes that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and outlines known risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The label also advises that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the label does not provide specific guidance on the optimal duration of use for fracture prevention, noting that the optimal duration has not been determined and that for low-risk patients, discontinuation after 3 to 5 years may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This leaves some ambiguity for clinicians and patients regarding long-term risk management.

Causation Considerations and Clinical Evidence

For affected patients, causation-related considerations are complex. ONJ can occur spontaneously, and its association with bisphosphonate use is based on epidemiological and clinical reports. In placebo-controlled clinical studies of Fosamax, the percentages of patients with symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), indicating that ONJ is not a common adverse event in the general osteoporosis population. However, the label acknowledges that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, and a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This pattern supports a causal relationship in susceptible individuals, particularly those with additional risk factors. In summary, scientific evidence establishes a plausible mechanistic link between Fosamax and ONJ through bisphosphonate-induced suppression of bone remodeling, with clinical data showing a temporal association and increased risk with longer exposure. Warnings in the prescribing information address this risk, but the rarity of ONJ in clinical trials and the multifactorial nature of the condition complicate individual causation assessments. Patients and clinicians should weigh the benefits of fracture reduction against the potential for ONJ, especially when considering long-term therapy or invasive dental procedures.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is osteonecrosis of the jaw (ONJ)?

Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region. It often presents with pain, swelling, infection, or drainage, and is diagnosed based on clinical examination and imaging. It can occur spontaneously but is often associated with dental procedures or local infection.

How does Fosamax cause osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate that inhibits bone resorption by suppressing osteoclast activity. This can impair the jawbone's ability to repair microdamage and respond to stressors, predisposing it to necrosis. Animal studies have shown that alendronate alters jawbone properties, compromising structural integrity (https://pubmed.ncbi.nlm.nih.gov/40345077/).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (tooth extraction, implants, boney surgery), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders like periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How long does it take for ONJ to develop after starting Fosamax?

The time to onset of ONJ symptoms can range from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk may increase with longer duration of exposure.

Does stopping Fosamax reduce the risk of ONJ?

For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Most patients have relief of symptoms after stopping the drug.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.